Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : International Journal of Cell and Biomedical Science

Therapeutic Potential of Secretome-Derived Wharton's Jelly Mesenchymal Stem Cells in Psoriasis Vulgaris: A Case Study Azzahara, Salma Yasmine; Agustina, Rita; Prawitasari, Salindri
International Journal of Cell and Biomedical Science Vol 2 No 5 (2023)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v2i5.37

Abstract

Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Case: In this report, we discuss our findings about a 47-years old psoriasis suffering male patient with a Psoriasis Area Severity Index (PASI) score of 10.8, treated with Wharton’s Jelly Mesenchymal Stem Cells-derived Secretome (S-MSCs). Remarkably, complete regression was recorded within a treatment period of a week only. Result: The patient demonstrated a decrease in PASI, from 10.8 to 3.2 after 1 infusion and followed by 4 intramuscular injections of S-MSCs. Bioactive factors secreted by MSCs, cytokines and growth factors, are very likely to be the principal molecules which play a vital role in inflammatory modulation and skin tissue regeneration. No serious adverse events were noted for the patient as a result of secretome infusion and intramuscular injection. Conclusion: This report demonstrates safety and promises to be an effective strategy using S-MSCs treatment for managing the psoriatic issue and, thus, may offer as an alternative approach to overcome the limitations of the cell-based therapy.
Anticancer effectiveness of Artemisia annua ethanol extract against MDAMB-231 cancer cells Agustina, Rita; Ari, Psn Masruri Sulistiyanto; Sadikin, Nadya Audina N
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.68

Abstract

Background: Breast cancer remains one of the leading causes of cancer deaths worldwide, with triple-negative breast cancer (TNBC) posing a significant therapeutic challenge due to its lack of hormonal receptors and resistance to conventional treatment. Artemisia annua L., a medicinal plant traditionally used in Chinese medicine, has received attention for its diverse bioactive compounds, including flavonoids, phenolic acids, and sesquiterpene lactones, which exhibit potential anticancer properties. This study aims to evaluate the in vitro cytotoxic effect of A. annua ethanol extract against MDA-MB-231 human breast cancer cells using the MTT assay. Methods: Extracts were prepared in 10% DMSO and tested at concentrations ranging from 0 to 1000 µg/mL. MDA-MB-231 cells were seeded in 96-well plates and incubated for 24 h before treatment. Post-treatment, cell viability was assessed via MTT assay, and absorbance was measured at 595 nm. The percentage of cytotoxicity was calculated, and the IC₅₀ value was determined through linear regression analysis. Results: The results showed a clear cytotoxic response depending on the dose, with the extract achieving an IC₅₀ value of 56.83 µg·mL-¹ indicating a fairly strong correlation between concentration and cytotoxicity. These findings indicate that A. annua contains bioactive compounds that are able to inhibit cancer cell proliferation. Conclusion: In conclusion, Artemisia annua ethanol extract showed moderate cytotoxic activity against MDA-MB-231 cells, supporting its potential as a complementary therapeutic agent for TNBC. Further studies are needed to elucidate its molecular mechanisms and evaluate its efficacy in vivo.
Harnessing the Innate Effector: A Narrative Review of Advancing Strategies in CAR Engineering, Metabolic Reprogramming, and TME Resistance of Natural Killer Cells for Cancer Immunotherapy Agustina, Rita; Lestari, Endah Agustina; Sidiq, Husni Ahmad; Nazar, M. Ariq
International Journal of Cell and Biomedical Science Vol 4 No 11 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i11.70

Abstract

Natural Killer (NK) cell-based immunotherapy is rapidly emerging as a promising modality for cancer treatment. As pivotal players in the innate immune system, cells independently recognize and eliminate malignant cells without prior sensitization, offering distinct advantages over other cell-based therapies. This review highlights the current landscapes of NK cell adoptive therapy, from fundamental biology to cutting-edge clinical applications. It highlights how advancing NK cell sources, including peripheral blood, umbilical cord blood, established cell lines, and the increasingly significant induced pluripotent stem cells (iPSCs), are driving wider, more standardized therapeutic use. The multifaceted strategies employed to enhance NK cell efficacy are being explored, including advanced expansion protocols and sophisticated genetic engineering techniques such as the introduction of Chimeric Antigen Receptors (CARs) and modifications to bolster antibody-dependent cellular cytotoxicity. Additionally, it also addresses the significant hurdles that remain, primarily the immunosuppressive tumor microenvironment (TME), and discusses innovative strategies being developed to overcome these challenges. By synthesizing preclinical data and results from the latest clinical trials, this review highlights the remarkable progress and bright future of NK cell therapy as a safer, effective, and more accessible cornerstone of cancer treatment.